Sanofi-Aventis on the Prowl | Free Investing

Sanofi-Aventis on the Prowl

Submitted by Free Investing on Tue, 07/06/2010 - 04:54

The Burrill Report submits: by Marie DaghlianEver since CEO Chris Veihbacher took the helm of France’s largest pharmaceutical company in September 2008, he has actively looked outside Sanofi-Aventis (SNY) for ways to stem the impending loss of over one third of its revenue from patent expirations. A Burrill Report analysis shows that he has spent $17 billion to expand and diversify the company, including more than $9 billion in acquisitions ranging from small biotechs to companies focused on generic drugs, animal health, and emerging markets. Now, reports say he’s ready to eclipse that in a single deal. Complete Story »

All original content is Free and Open.
All syndicated content is © the original authors.

Countries for Investment: Argentina, Australia, Belarus, Belize, Bolivia, Brazil, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Ecuador, Egypt, England, Finland, France, Germany, Guatemala, Honduras, Iceland, India, Iraq, Iran, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Pakistan, Paraguay, Peru, Philippines, Poland, Portugal, Russia, Scotland, Slovakia, Slovenia, Sweden, Syria, Thailand, Turkey, Ukraine, United Arabic Emirates, Uruguay, Venezuela, Vietnam and others.

US States for Investing: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming